M
Mira Pharmaceuticals Inc
NASDAQ:MIRA
Mira Pharmaceuticals Inc
NASDAQ:MIRA
Price:
1.33
USD
4.72%
Market Cap:
$55.7m
Relative Value
There is not enough data to reliably calculate the relative value of MIRA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MIRA
Relative Value
Base Case
Not Available
Multiples Across Competitors
MIRA Competitors Multiples
Mira Pharmaceuticals Inc Competitors
Mira Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
M
|
Mira Pharmaceuticals Inc
NASDAQ:MIRA
|
52.6m USD | 0 | -1.8 | -6.3 | -6.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
969.6B USD | 14.9 | 47 | 31.7 | 33.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
588.3B USD | 6.2 | 21.9 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
293.6B CHF | 4.8 | 31.2 | 13.1 | 15.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
250.1B CHF | 5.7 | 23 | 14.2 | 18.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
239.2B GBP | 5.5 | 31.5 | 17.4 | 24.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.1B USD | 4.6 | 16.5 | 10.3 | 12.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD | 2.5 | 19.8 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.9B USD | 2.6 | 17.6 | 7.4 | 9.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
